VitalHub Corp. to Acquire MedCurrent Corporation
VitalHub Corp. to Acquire MedCurrent Corporation
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the "Company" or "VitalHub") is pleased to announce that it has signed a definitive agreement (the "Definitive Agreement") to acquire MedCurrent Corporation and its subsidiaries ("MedCurrent"), by way of a court-approved plan of arrangement under the provisions of the Business Corporations Act (Ontario) (the "Transaction").
多倫多,2024年7月30日(環球通訊社)——VitalHub Corp.(多倫多證券交易所股票代碼:VHI)(OTCQX:VHIBF)(“公司” 或 “VitalHub”)欣然宣佈,它已簽署一項最終協議(“最終協議”),根據該條款通過法院批准的安排計劃收購MedCurrent Corporation及其子公司(“MedCurrent”)《商業公司法》(安大略省)(“交易”)。
MedCurrent is a physician-founded Clinical Decision Support (CDS) company focused on improving the quality of care and managing health system costs through its innovative and scalable solution, OrderWise. OrderWise enhances the clinical decision-making process within real-time to determine the appropriateness of a test using evidence-based guidelines and artificial intelligence (AI) integrated at the point of care. To date, the development of OrderWise has been primarily focused on improving appropriateness of orders for medical imaging tests. MedCurrent provides its solutions in over 80 customer installations in Canada, the United Kingdom, the United States of America, and Australia.
MedCurrent是一家由醫生創立的臨床決策支持(CDS)公司,致力於通過其創新和可擴展的解決方案OrderWise來提高護理質量和管理醫療系統成本。OrderWise 使用基於證據的指南和集成在護理點的人工智能 (AI),實時增強臨床決策流程,以確定測試的適當性。迄今爲止,OrderWise的開發主要側重於提高醫學影像測試訂單的適用性。MedCurrent 在加拿大、英國、美利堅合衆國和澳大利亞的 80 多個客戶設施中提供解決方案。
Hospital diagnostics, including medical imaging and laboratory testing, are critical components of healthcare delivery, accounting for a sizable portion of hospital expenditures1. In Canada alone, hospitals spend over $3 billion annually on medical imaging and $5.9 billion on laboratory testing2. Addressing inefficiencies and improving appropriateness in these areas is essential to reducing costs and enhancing patient outcomes. The Conference Board of Canada estimates that in 2022, average wait times were 67 days for a CT scan and 133 days for an MRI, significantly exceeding the acceptable 30-day standard3. These delays result in a net loss of $3.5 billion in GDP annually. Additionally, up to 30% of certain medical tests, procedures, and treatments are potentially unnecessary, according to the Canadian Institute for Health Information (CIHI)4. By integrating MedCurrent's CDS solutions, VitalHub aims to reduce these inefficiencies, with a view to lowering healthcare costs and improving patient care.
醫院診斷,包括醫學成像和實驗室檢測,是醫療服務的關鍵組成部分,佔醫院支出的很大一部分1。僅在加拿大,醫院每年在醫學成像方面的支出就超過30億美元,在實驗室測試上的支出爲59億加元2。解決這些領域的效率低下問題和提高適用性對於降低成本和改善患者預後至關重要。加拿大會議委員會估計,2022年,Ct掃描的平均等待時間爲67天,核磁共振成像的平均等待時間爲133天,大大超過了可接受的30天標準3。這些延誤導致每年的GDP淨損失35億美元。此外,根據加拿大衛生信息研究所(CIHI)4的數據,多達30%的某些醫學檢查、程序和治療可能是不必要的。通過整合MedCurrent的CDS解決方案,VitalHub旨在減少這些效率低下的情況,以降低醫療保健成本和改善患者護理。
VitalHub's acquisition of MedCurrent aligns with VitalHub's strategic vision to integrate cutting-edge technology solutions that streamline healthcare delivery. MedCurrent's OrderWise platform, focused on optimizing diagnostic orders, will complement VitalHub's existing Patient Flow software suite, providing a comprehensive solution to manage healthcare resources more effectively.
VitalHub對MedCurrent的收購符合VitalHub的戰略願景,即整合尖端技術解決方案,簡化醫療保健交付。MedCurrent的OrderWise平台專注於優化診斷訂單,將補充VitalHub現有的Patient Flow軟件套件,爲更有效地管理醫療資源提供全面的解決方案。
"This acquisition represents a significant step forward in our mission to enhance healthcare delivery through technology," said Dan Matlow, CEO of VitalHub. "MedCurrent's unique CDS software addresses a clear and critical need in the healthcare system. By integrating MedCurrent's solutions with our existing offerings, we believe that we can significantly reduce unnecessary tests and procedures, ultimately lowering costs and improving patient care. We are excited about the potential to expand MedCurrent's reach internationally and enhance our collective impact on global healthcare systems."
VitalHub首席執行官丹·馬特洛表示:“此次收購代表着我們在通過技術加強醫療保健服務的使命方面向前邁出了重要一步。”“MedCurrent獨特的CDS軟件滿足了醫療保健系統的明確而關鍵的需求。通過將MedCurrent的解決方案與我們的現有產品相結合,我們相信我們可以顯著減少不必要的測試和程序,最終降低成本並改善患者護理。我們對擴大MedCurrent的國際影響力並增強我們對全球醫療系統的集體影響力的潛力感到興奮。”
"We are thrilled to join forces with VitalHub, a company that shares our commitment to improving healthcare through innovation. This partnership will allow us to accelerate the development and deployment of our solutions, reaching more healthcare providers and patients worldwide," said Dr. Steve Herman, Founder and CEO of MedCurrent.
“我們很高興與VitalHub合作,該公司與我們一樣致力於通過創新改善醫療保健。這種夥伴關係將使我們能夠加快解決方案的開發和部署,覆蓋全球更多的醫療保健提供者和患者。” MedCurrent創始人兼首席執行官史蒂夫·赫爾曼博士說。
TRANSACTION CONDITIONS AND TIMING
交易條件和時間
VitalHub has agreed to acquire MedCurrent for total consideration of up to approximately C$34 million (assuming all earn-outs are achieved), including a cash payment of approximately C$12 million on closing (which amount is subject to customary working capital adjustments and other similar closing adjustments), and additional earn-out consideration up to a maximum of approximately C$21.875 million) based on annual performance over 36 months.
VitalHub已同意收購MedCurrent,總對價高達約3,400萬加元(假設所有收益均已實現),其中包括在收盤時支付的約1200萬加元的現金(該金額受常規營運資本調整和其他類似的收盤調整影響),以及根據36個月的年度業績計算的額外收益對價,最高約爲2187.5萬加元)。
The Transaction will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) and will require the approval of at least 662⁄3% of votes cast by MedCurrent shareholders at a special meeting of MedCurrent shareholders, the timing of which will be approved by the court. Upon completion of the Transaction, MedCurrent will become a wholly owned subsidiary of VitalHub.
該交易將通過法院批准的《商業公司法》(安大略省)下的安排計劃生效,並且需要批准MedCurrent股東在MedCurrent股東特別會議上所投的至少662⁄3%的選票,具體時間將由法院批准。交易完成後,MedCurrent將成爲VitalHub的全資子公司。
Directors, officers, and certain other shareholders of MedCurrent, holding approximately 79.81% of the issued and outstanding common shares of MedCurrent, calculated on an as-converted to common share basis, have entered into voting support agreements pursuant to which they have agreed to vote their MedCurrent common shares in favour of the Transaction. In addition to the shareholder and court approval, the Transaction is subject to applicable regulatory approvals and third party consents and the satisfaction of certain other closing conditions customary in transactions of this nature. The Transaction is expected to close at the beginning of September, 2024.
MedCurrent的董事、高級管理人員和某些其他股東持有MedCurrent已發行和流通普通股的約79.81%(按轉換爲普通股計算),他們已經簽訂了投票支持協議,根據該協議,他們同意將其MedCurrent普通股投票支持該交易。除了股東和法院的批准外,該交易還需要獲得適用的監管部門批准和第三方的同意,並滿足此類性質交易中常見的某些其他成交條件。該交易預計將於2024年9月初完成。
VitalHub's legal advisors for the Transaction are Torkin Manes LLP. Toronto-based Morrison Park Advisors and Rotterdam-based IMAP Netherlands served as MedCurrent's exclusive financial advisors, while Norton Rose Fulbright Canada LLP acted as legal advisor.
VitalHub爲該交易提供的法律顧問是托爾金·馬內斯律師事務所。總部位於多倫多的莫里森公園顧問公司和總部位於鹿特丹的IMAP Netherlands擔任MedCurrent的獨家財務顧問,而加拿大諾頓羅斯富布賴特律師事務所則擔任法律顧問。
Further details of the Transaction are set out in the Definitive Agreement that is available under Vitalhub's corporate profile on SEDAR+ at .
該交易的更多細節載於最終協議,該協議可在SEDAR+的Vitalhub公司簡介中查閱,網址爲。
ABOUT MEDCURRENT
關於 MEDCURRE
Headquartered in Toronto, Canada, MedCurrent Corporation is focused on improving the quality of care and managing health system costs through its innovative Clinical Decision Support (CDS) platform, enabling real-time, evidence-based guidelines integrated at the point of care to improve health and healthcare delivery. MedCurrent serves 80+ organizations throughout Canada, the United Kingdom, the United States of America, and Australia with its 15 team members based in Canada and the United Kingdom.
總部位於加拿大多倫多的MedCurrent Corporation專注於通過其創新的臨床決策支持(CDS)平台提高護理質量和管理衛生系統成本,在醫療點整合實時、循證的指南,以改善健康和醫療保健的提供。MedCurrent爲加拿大、英國、美利堅合衆國和澳大利亞的80多個組織提供服務,其15名團隊成員分佈在加拿大和英國。
ABOUT VITALHUB
關於 VITALHUB
Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.
專爲健康與公共服務提供商設計的軟件,旨在簡化用戶體驗並優化結果。
VitalHub is a leading software company dedicated to empowering Health and Human Services providers. Our clients include hospitals, regional health authorities, mental health and addictions services providers for children and adults, long-term care facilities, home health agencies, correctional services, and community and social services providers.
VitalHub是一家領先的軟件公司,致力於爲健康與公共服務提供商提供支持。我們的客戶包括醫院、地區衛生當局、兒童和成人的心理健康和成癮服務提供商、長期護理機構、家庭健康機構、懲教服務機構以及社區和社會服務提供商。
VitalHub's comprehensive suite of SaaS solutions include:
VitalHub 的全面 SaaS 解決方案套件包括:
- Electronic Health Record (EHR), Case Management, Care Coordination, and Optimization
- Patient Flow, Operational Visibility, and Patient Journey Optimization
- Workforce Automation
- 電子醫療記錄 (EHR)、病例管理、護理協調和優化
- 患者流量、運營可見性和患者旅程優化
- 勞動力自動化
The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe.
該公司制定了強有力的雙管齊下的增長戰略,瞄準其產品套件中的有機增長機會,並推行積極的併購計劃。目前,VitalHub爲加拿大、美國、英國、澳大利亞、中東和歐洲的1,000多名客戶提供服務。
VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 400 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol "VHIBF".
VitalHub總部位於加拿大多倫多,在斯里蘭卡設有離岸開發中心。VitalHub團隊由全球400多名團隊成員組成。該公司在多倫多證券交易所(TSX)上市,股票代碼爲 “VHI”,在場外市場OTCQX交易所上市,股票代碼爲 “VHIBF”。
CONTACT INFORMATION
聯繫信息
VitalHub Corp.
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
dan.matlow@vitalhub.com
VitalHub 公司
丹·馬特洛
首席執行官、董事
(416) 727-9061
dan.matlow@vitalhub.com
CAUTIONARY STATEMENT
警示聲明
This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer's business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer's prospective financial performance or financial position. The forward-looking information in this news release includes reference to disclosure about the terms of the Transaction, about MedCurrent, including its historical revenue and future recurring revenue, and about potential synergies among existing offerings in the issuer's patient flow products as well as the potential for the international application of MedCurrent's product offerings. VitalHub made certain material assumptions, including but not limited to: prevailing market conditions; general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of VitalHub and MedCurrent to execute and achieve its business objectives, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to: adverse market conditions; the inability of VitalHub and MedCurrent to successfully integrate operations; reliance on key and qualified personnel; and regulatory and other risks associated with the medical and technology industries in general. The foregoing list of material risk factors and assumptions is not exhaustive. VitalHub assumes no obligation to update or revise the forward-looking information in this news release unless it is required to do so under Canadian securities legislation.
本新聞稿包含加拿大證券立法所指的 “前瞻性信息”。前瞻性信息通常是指有關發行人業務、資本或運營的具有前瞻性的信息,包括有關發行人預期財務業績或財務狀況的面向未來的財務信息。本新聞稿中的前瞻性信息包括有關交易條款、MedCurrent(包括其歷史收入和未來經常性收入)的披露、發行人患者流產品現有產品之間的潛在協同效應以及MedCurrent產品在國際上的應用潛力的披露。VitalHub做出了某些重大假設,包括但不限於:當前的市場狀況;一般業務、經濟、競爭、政治和社會的不確定性;延遲或未能獲得董事會、股東或監管機構的批准;以及VitalHub和MedCurrent執行和實現其業務目標的能力,在本新聞稿中提供前瞻性信息。無法保證此類陳述會被證明是準確的,因爲實際結果和未來事件可能與此類陳述中的預期存在重大差異。因此,讀者不應過分依賴前瞻性陳述。由於某些重大風險因素,實際結果可能與本新聞稿中的前瞻性信息有所不同。這些風險因素包括但不限於:不利的市場狀況;VitalHub和MedCurrent無法成功整合業務;對關鍵和合格人員的依賴;以及與整個醫療和技術行業相關的監管和其他風險。上述重大風險因素和假設清單並不詳盡。除非加拿大證券立法要求更新或修改本新聞稿中的前瞻性信息,否則VitalHub沒有義務更新或修改本新聞稿中的前瞻性信息。
- CD Howe Institute, Commentary No. 533, "What the Doctor Ordered: Improving the Use and Value of Laboratory Testing".
- Canadian Institute for Health Information, "Hospital Spending", September 21, 2023.
- Canadian Association of Radiologists, "Addressing the Medical Imaging Dilemma in Canada: Restoring Timely Access for Patients Post-Pandemic."
- Canadian Institute for Health Information, "Unnecessary Care in Canada", April 2017.
- CD Howe研究所,第533號評論,“權宜之計:改善實驗室測試的使用和價值”。
- 加拿大衛生信息研究所,“醫院支出”,2023年9月21日。
- 加拿大放射科醫師協會,“解決加拿大的醫學影像困境:恢復疫情後患者的及時就診。”
- 加拿大衛生信息研究所,“加拿大不必要的護理”,2017年4月。